OSI muscles up

It is a fact of life that the more advanced a compound, the more leverage a company has when it comes to partnering. With $385 million in the bank, OSI Pharmaceuticals Inc. could have waited until after Phase III or even after FDA approval to license its OSI-774 cancer compound, which is

Read the full 525 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers